The global Dipeptide Peptidase 4 (DPP-4) Inhibitors market was valued at US$ 8984.2 million in 2020 and is expected to reach US$ 10840 million by the end of 2027, growing at a CAGR of 2.3% during 2021-2027.
Dipeptide Peptidase 4 (DPP-4) Inhibitors are a class of oral diabetes drugs that work by blocking the action of DPP-4, an enzyme which destroys a group of gastrointestinal hormones called incretins. Incretins help stimulate the production of insulin when it is needed (e.g. after eating) and reduce the production of glucagon by the liver when it is not needed (e.g. during digestion). They also slow down digestion and decrease appetite. So by protecting incretins from damage, DPP-4 inhibitors help regulate blood glucose levels.
Januvia (Sitagliptin), Galvus (Vildagliptin), Onglyza (Saxagliptin), Tradjenta (Linagliptin) are the major DPP-4 drugs in the market.
Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market: Drivers and Restrains
The research report has incorporated the analysis of different factors that augment the market’s growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of production about the global market and about each type from 2016 to 2027. This section mentions the volume of production by region from 2016 to 2027. Pricing analysis is included in the report according to each type from the year 2016 to 2027, manufacturer from 2016 to 2021, region from 2016 to 2021, and global price from 2016 to 2027.
A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market expert’s opinions have been taken to understand the market better.
Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market: Segment Analysis
The research report includes specific segments by region (country), by manufacturers, by Type and by Application. Each type provides information about the production during the forecast period of 2016 to 2027.
Key Companies profiled in this report are Merck, Eli Lilly, AstraZenica, Boehringer Ingelheim, Takeda Pharmaceutical Company, BMS and more in terms of market share by sales, revenue, average pricing, product type, margins, recent developments etc.
Segment by Type
Segment by Application
Table of Content:
1 Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Overview
2 Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Competition by Manufacturers
3 Dipeptide Peptidase 4 (DPP-4) Inhibitors Retrospective Market Scenario by Region
4 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Historic Market Analysis by Type
5 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Historic Market Analysis by Application
6 Key Companies Profiled
7 Dipeptide Peptidase 4 (DPP-4) Inhibitors Manufacturing Cost Analysis
8 Marketing Channel, Distributors and Customers
9 Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Dynamics
10 Global Market Forecast
11 Research Finding and Conclusion
12 Methodology and Data Source
Company Name: The Market Reports
Contact Person: Shirish Gupta